CompletedPhase 1NCT00611728

Ph I SU011248 + Irinotecan in Treatment of Pts w MG

Studying Glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Duke University
Principal Investigator
David A. Reardon, MD
Duke Health
Intervention
SU011248 & Irinotecan(drug)
Enrollment
25 enrolled
Eligibility
18 years · All sexes
Timeline
20082010

Study locations (1)

Collaborators

Pfizer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00611728 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma

← Back to all trials